Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Total Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals has reported Total Non-Current Liabilities over the past 3 years, most recently at $517.0 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 28.06% to $517.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $517.0 million through Dec 2025, up 28.06% year-over-year, with the annual reading at $517.0 million for FY2025, 35.21% up from the prior year.
  • Total Non-Current Liabilities was $517.0 million for Q4 2025 at Telix Pharmaceuticals, up from $403.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $517.0 million in Q4 2025 and troughed at $59.9 million in Q4 2023.
  • The 3-year median for Total Non-Current Liabilities is $403.7 million (2024), against an average of $326.9 million.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 574.17% in 2024 and then increased 28.06% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $59.9 million in 2023, then skyrocketed by 574.17% to $403.7 million in 2024, then increased by 28.06% to $517.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Total Non-Current Liabilities are $517.0 million (Q4 2025), $403.7 million (Q4 2024), and $59.9 million (Q4 2023).